The kinin system: suggestions to broaden some prevailing concepts
Section snippets
Acknowledgements
These studies were supported in part by NIH-National Heart, Lung and Blood Institute grants #HL36473 and #HL58118. We are grateful to Ms. Sara Blaszczak for editorial assistance.
References (30)
- et al.
Pathways for bradykinin formation and inflammatory disease
J. Allergy Clin. Immunol.
(2002) - et al.
Kallikrein and prekallikrein of the isolated basolateral membrane of rat kidney
Kidney Int.
(1982) - et al.
Potentiation of bradykinin actions by ACE inhibitors
Trends Endocrinol. Metab.
(1999) - et al.
Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum
Peptides
(2000) - et al.
[Phe8Ψ(CH2–NH)Arg9]bradykinin, a B2 receptor selective agonist which is not broken down by either kininase I or kininase II
Eur. J. Pharmacol.
(1988) - et al.
Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors
J. Biol. Chem.
(2000) - et al.
Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase
Peptides
(1984) - et al.
Mouse angiotensin-converting enzyme is a protein composed of two homologous domains
J. Biol. Chem.
(1989) - et al.
Novel mode of action of angiotensin I converting enzyme inhibitors. Direct activation of bradykinin B1 receptor
J. Biol. Chem.
(2002) - et al.
Bioregulation of kinins: kallikreins, kininogens, and kininases
Pharmacol. Rev.
(1992)
Structure–activity relationships of kinins
The B1 receptors for kinins
Pharmacol. Rev.
SQ14,225 (d-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme
J. Pharmacol. Exp. Ther.
ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin
Cardiovasc. Res.
Perspectives on the early history of angiotensin-converting enzyme—recent follow-ups
Cited by (19)
Kininases
2018, Encyclopedia of Endocrine DiseasesCharacterization of the kallikrein-kinin system during the bovine ovulation process
2011, PeptidesCitation Excerpt :The kallikrein–kinin system (KKS) is an important mediator of inflammatory responses acting on vasodilatation, activation and inactivation of proteases, stimulation of prostaglandin biosynthesis as well as induction of smooth muscle contractility [3,24]. Kininogen (KNG) is a precursor protein of the KKS; plasma kallikrein uses KNG as a substrate to generate bradykinin while tissue kallikrein liberates kallidin that is cleaved to the bradykinin [3,11]. Bradykinin is a nonapeptide kinin, the main mediator of KKS responses [3,8].
Structure and Function of the Heart
2011, Pediatric Critical Care: Expert Consult Premium EditionStructure and Function of the Heart
2011, Pediatric Critical CareCarboxypeptidase M and kinin B1 receptors interact to facilitate efficient B1 signaling from B2 agonists
2008, Journal of Biological ChemistryCitation Excerpt :Although interactions between peptide receptors and related peptidases have not been extensively studied, recent evidence indicates that ACE and B2 kinin receptor do interact on the cell surface (44, 45). Because ACE readily inactivates bradykinin, it was previously thought that ACE inhibitors enhance B2R signaling solely by blocking degradation of the B2 agonist (46). However, several reports provide evidence that ACE inhibitors potentiate/resensitize B2R signaling apart from their ability to block bradykinin degradation (e.g. with ACE-resistant B2 agonists) (47).
Kinins and Endothelin
2008, Seldin and Giebisch's The Kidney